The SMC has once again rejected a submission from MSD for Remicade (infliximab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.  This is the third time the SMC has rejected Remicade for this indication.

For more details, go to: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/374_07_infliximab_100mg_powder_for_intravenous_infusion_Remicade/infliximab_Remicade_RESUBMISSION